Biotech leader extends lease at 451 D Street
CBRE/New England announced that Acetylon Pharmaceuticals, the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, renewed its 13,600 square foot lease at 451 D Street in Boston’s Seaport District. Acetylon occupies both laboratory and office space in the building.
McPherson Corporation’s Keith Coulter represented Acetylon in the transaction. CBRE/NE’s Bill Crean and Jonathan Freni represented owner Meritage Properties. The building is owned in a joint venture between Meritage Properties, State Street Global Advisors and Commonwealth Ventures.
“We are thrilled that Acetylon Pharmaceuticals, another high-quality and innovative company, will continue to call 451 D home,” said Erin Shaw, Managing Director at Meritage Properties. “451 D has a unique ability to accommodate the needs of both large and small tenants in a highly amenitized industrial chic environment, just steps from The Lawn on D.”
“451 D Street has the vibrant location, terrific on-site amenities and community of like-minded tenants that make it appealing to practically every organization seeking a Boston presence,” added Bill Crean, Senior Vice President/Partner at CBRE/NE. “We are glad that Acetylon continues to see the value that 451 D Street offers for its employees and business.”
451 D Street offers numerous amenities including on-site parking, a fitness center and shuttle service to North and South Stations. The property is currently undergoing a lobby renovation and the addition of a 3,000 SF tenant amenity center featuring a lounge area, kitchen, games and conference center.
About Acetylon
Acetylon Pharmaceuticals, Inc., based in Boston, Massachusetts, is a leader in the development of novel small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The Company’s epigenetic drug discovery platform has yielded a proprietary portfolio of optimized Class I and Class II histone deacetylase (HDAC) selective compounds for oral administration. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases including cancer, sickle cell disease and beta-thalassemia, and autoimmune and neurodegenerative diseases. Acetylon’s lead drug candidates, ricolinostat (ACY-1215) and ACY-241, are selective HDAC6 inhibitors currently in Phase 2 and Phase 1b clinical development for the treatment of multiple myeloma, respectively. In 2013, the Company announced a strategic collaboration agreement with Celgene Corporation, which includes an exclusive option for the future acquisition of Acetylon by Celgene. Acetylon’s scientific founders are affiliated with Harvard University, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, and Harvard Medical School.www.acetylon.com.
About CBRE/New England
CB Richard Ellis – N.E. Partners, LP, a joint venture with CBRE Group, Inc. has offices in Massachusetts, Connecticut, Rhode Island, Maine and New Hampshire. Please visit our website at www.cbre-ne.com. CBRE Group, Inc. (NYSE:CBG), a Fortune 500 and S&P 500 company headquartered in Los Angeles, is the world’s largest commercial real estate services and investment firm (in terms of 2014 revenue). The Company has more than 70,000 employees (excluding affiliates), and serves real estate owners, investors and occupiers through more than 400 offices (excluding affiliates) worldwide. CBRE offers strategic advice and execution for property sales and leasing; corporate services; property, facilities and project management; mortgage banking; appraisal and valuation; development services; investment management; and research and consulting.
